LOS ANGELES--(BUSINESS WIRE)--Response Genetics Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today that it will present data from eight studies investigating the clinical utility of its proprietary technology, RGI-1, during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 4 to June 8, 2010. Data will highlight advances in diagnostic testing in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) and the scientific understanding of tumor biomarkers.
